Jefferies Boosts Price Target on Vanda (VNDA) to $11 Amid Sell-Off
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Lazard Capital Defends Vanda (VNDA), Calls Reports 'Inflammatory'
June 19, 2013 1:56 PM EDTLazard Capital today maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ: VNDA) with a price target of $19.00. The note follows negative comments in the Street.com, which led to a sharp sell-off.
Analyst Joshua Schimmer called comments a "surprisingly inflammatory assessment of tasimelteon's approval... More
Vanda Pharmaceuticals (VNDA) Sinks as Red Flags Raised
June 19, 2013 8:14 AM EDTVanda Pharmaceuticals, Inc. (NASDAQ: VNDA) is under heavy pressure early following a negative article by The Street's Adam Feuerstein. Shares are down 16%.
"Vanda Pharmaceuticals (VNDA) tells a pretty compelling story about the development of tasimelteon for the treatment of a rare... More
